1
|
Delage L, Lambert M, Bardel É, Kundlacz C, Chartoire D, Conchon A, Peugnet AL, Gorka L, Auberger P, Jacquel A, Soussain C, Destaing O, Delecluse HJ, Delecluse S, Merabet S, Traverse-Glehen A, Salles G, Bachy E, Billaud M, Ghesquières H, Genestier L, Rouault JP, Sujobert P. BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood 2023; 141:1209-1220. [PMID: 36375119 DOI: 10.1182/blood.2022016943] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 10/11/2022] [Accepted: 11/01/2022] [Indexed: 11/16/2022] Open
Abstract
Understanding the functional role of mutated genes in cancer is required to translate the findings of cancer genomics into therapeutic improvement. BTG1 is recurrently mutated in the MCD/C5 subtype of diffuse large B-cell lymphoma (DLBCL), which is associated with extranodal dissemination. Here, we provide evidence that Btg1 knock out accelerates the development of a lethal lymphoproliferative disease driven by Bcl2 overexpression. Furthermore, we show that the scaffolding protein BCAR1 is a BTG1 partner. Moreover, after BTG1 deletion or expression of BTG1 mutations observed in patients with DLBCL, the overactivation of the BCAR1-RAC1 pathway confers increased migration ability in vitro and in vivo. These modifications are targetable with the SRC inhibitor dasatinib, which opens novel therapeutic opportunities in BTG1 mutated DLBCL.
Collapse
Affiliation(s)
- Lorric Delage
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Mireille Lambert
- Université de Paris, Institut Cochin, INSERM U1016, Plateforme BioMecan'IC, Biomécanique de la cellule, Paris, France
| | - Émilie Bardel
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Cindy Kundlacz
- Institut de Génomique Fonctionnelle de Lyon, Centre National de la Recherche Scientifique UMR5242, Université Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Dimitri Chartoire
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Axel Conchon
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Anne-Laure Peugnet
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Lucas Gorka
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Patrick Auberger
- Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France
| | - Arnaud Jacquel
- Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France
| | - Carole Soussain
- Institut Curie, Site de Saint-Cloud, Hematologie, et INSERM U932 Institut Curie, PSL Research University, Paris, France
| | - Olivier Destaing
- Centre de Recherche UGA, INSERM U1209, Institute for Advanced Biosciences, Grenoble, France
| | | | | | - Samir Merabet
- Institut de Génomique Fonctionnelle de Lyon, Centre National de la Recherche Scientifique UMR5242, Université Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Alexandra Traverse-Glehen
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Gilles Salles
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Emmanuel Bachy
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Marc Billaud
- INSERM Unité Mixte de Recherche (UMR)-U1052, Centre National de la Recherche UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Hervé Ghesquières
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Laurent Genestier
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Jean-Pierre Rouault
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
- INSERM Unité Mixte de Recherche (UMR)-U1052, Centre National de la Recherche UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Pierre Sujobert
- Centre International de Recherche en Infectiologie (Team LIB), Université Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France
- Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| |
Collapse
|
2
|
Lefevre C, Chartoire D, Ferraz JC, Verdier T, Pinteur C, Chanon S, Pesenti S, Vieille-Marchiset A, Genestier L, Vidal H, Mey A. Obesity activates immunomodulating properties of mesenchymal stem cells in adipose tissue with differences between localizations. FASEB J 2021; 35:e21650. [PMID: 33993539 DOI: 10.1096/fj.202002046rr] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 04/21/2021] [Accepted: 04/21/2021] [Indexed: 01/02/2023]
Abstract
Mesenchymal stem cells from healthy adipose tissue are adipocytes progenitors with immunosuppressive potential that are used for years in cell therapy. Whether adipose stem cells (ASC) may prevent inflammation in early obesity is not known. To address this question, we performed a kinetic study of high-fat (HF) diet induced obesity in mice to follow the immune regulating functions of adipose stem cells (ASC) isolated from the subcutaneous (SAT) and the visceral adipose tissue (VAT). Our results show that, early in obesity and before inflammation was detected, HF diet durably and differently activated ASC from SAT and VAT. Subcutaneous ASC from HF-fed mice strongly inhibited the proliferation of activated T lymphocytes, whereas visceral ASC selectively inhibited TNFα expression by macrophages and simultaneously released higher concentrations of IL6. These depot specific differences may contribute to the low-grade inflammation that develops with obesity in VAT while inflammation in SAT is delayed. The mechanisms involved differ from those already described for naïve cells activation with inflammatory cytokines and probably engaged metabolic activation. These results evidence that adipose stem cells are metabolic sensors acquiring an obesity-primed immunocompetent state in answer to depot-specific intrinsic features with overnutrition, placing these cells ahead of inflammation in the local dialog with immune cells.
Collapse
Affiliation(s)
- Camille Lefevre
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Dimitri Chartoire
- CRCL, Equipe Labellisée Ligue Contre le Cancer, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Oullins Cedex, France
| | - Jose Candido Ferraz
- Department of Physical Education and Sports Science, CAV, Federal University of Pernambuco (UFPE), Vitoria de Santo Antão, Brazil
| | - Thomas Verdier
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Claudie Pinteur
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Stéphanie Chanon
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Sandra Pesenti
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Aurélie Vieille-Marchiset
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Laurent Genestier
- CRCL, Equipe Labellisée Ligue Contre le Cancer, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Oullins Cedex, France
| | - Hubert Vidal
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| | - Anne Mey
- Univ Lyon, CarMeN Laboratory, INSERM U1060, INRAE 1397, INSA Lyon, Université Claude Bernard Lyon 1, Oullins Cedex, France.,Hospices Civils de Lyon, Faculté de Médecine, Hôpital Lyon Sud, Oullins Cedex, France
| |
Collapse
|
3
|
Carras S, Chartoire D, Mareschal S, Heiblig M, Marçais A, Robinot R, Urb M, Pommier RM, Julia E, Chebel A, Verney A, Bertheau C, Bardel E, Fezelot C, Courtois L, Lours C, Bouska A, Sharma S, Lefebvre C, Rouault JP, Sibon D, Ferrari A, Iqbal J, de Leval L, Gaulard P, Traverse-Glehen A, Sujobert P, Blery M, Salles G, Walzer T, Bachy E, Genestier L. Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. J Clin Invest 2021; 131:e139675. [PMID: 34043588 DOI: 10.1172/jci139675] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Accepted: 05/24/2021] [Indexed: 12/25/2022] Open
Abstract
Peripheral T cell lymphomas (PTCLs) represent a significant unmet medical need with dismal clinical outcomes. The T cell receptor (TCR) is emerging as a key driver of T lymphocyte transformation. However, the role of chronic TCR activation in lymphomagenesis and in lymphoma cell survival is still poorly understood. Using a mouse model, we report that chronic TCR stimulation drove T cell lymphomagenesis, whereas TCR signaling did not contribute to PTCL survival. The combination of kinome, transcriptome, and epigenome analyses of mouse PTCLs revealed a NK cell-like reprogramming of PTCL cells with expression of NK receptors (NKRs) and downstream signaling molecules such as Tyrobp and SYK. Activating NKRs were functional in PTCLs and dependent on SYK activity. In vivo blockade of NKR signaling prolonged mouse survival, demonstrating the addiction of PTCLs to NKRs and downstream SYK/mTOR activity for their survival. We studied a large collection of human primary samples and identified several PTCLs recapitulating the phenotype described in this model by their expression of SYK and the NKR, suggesting a similar mechanism of lymphomagenesis and establishing a rationale for clinical studies targeting such molecules.
Collapse
Affiliation(s)
- Sylvain Carras
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Dimitri Chartoire
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Sylvain Mareschal
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Maël Heiblig
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,Department of Hematology, Hospices Civils de Lyon, Lyon, France
| | - Antoine Marçais
- INSERM U1111, CNRS UMR 5308, Centre International de Recherche en Infectiologie, Lyon, France
| | - Rémy Robinot
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Mirjam Urb
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Roxane M Pommier
- Synergie Lyon Cancer, Plateforme de Bioinformatique "Gilles Thomas" Centre Léon Bérard, Lyon, France
| | - Edith Julia
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Amel Chebel
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Aurélie Verney
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | | | - Emilie Bardel
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Caroline Fezelot
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Lucien Courtois
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Camille Lours
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Alyssa Bouska
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Sunandini Sharma
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Christine Lefebvre
- Department of Genetics of Hematological Malignancies, Grenoble University Hospital, Grenoble, France.,INSERM U1209, CNRS UMR 5309, Grenoble Alpes University, Institute for Advanced Biosciences, Grenoble, France
| | - Jean-Pierre Rouault
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - David Sibon
- Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Laboratoire d'Excellence GR-Ex, Paris, France
| | - Anthony Ferrari
- Synergie Lyon Cancer, Plateforme de Bioinformatique "Gilles Thomas" Centre Léon Bérard, Lyon, France
| | - Javeed Iqbal
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Laurence de Leval
- Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne, Lausanne, Switzerland
| | - Philippe Gaulard
- INSERM U955, Université Paris-Est, Créteil, France.,Department of Pathology, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri-Mondor, Créteil, France
| | - Alexandra Traverse-Glehen
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,Department of Pathology, Hospices Civils de Lyon, Lyon, France
| | - Pierre Sujobert
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,Laboratory of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | | | - Gilles Salles
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,Department of Hematology, Hospices Civils de Lyon, Lyon, France
| | - Thierry Walzer
- INSERM U1111, CNRS UMR 5308, Centre International de Recherche en Infectiologie, Lyon, France
| | - Emmanuel Bachy
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,Department of Hematology, Hospices Civils de Lyon, Lyon, France
| | - Laurent Genestier
- UR LIB, Faculté de Médecine Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Lyon, France.,Centre de Recherche en Cancérologie de Lyon - Equipe Labellisée La Ligue 2017, INSERM U1052, Centre National de Recherche Scientifique (CNRS) UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| |
Collapse
|
4
|
Barba T, Harb J, Ducreux S, Koenig A, Mathias V, Rabeyrin M, Pouliquen E, Sicard A, Chartoire D, Dugast E, Defrance T, Morelon E, Brouard S, Dubois V, Thaunat O. Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes. Front Immunol 2019; 10:513. [PMID: 30949173 PMCID: PMC6435580 DOI: 10.3389/fimmu.2019.00513] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 02/26/2019] [Indexed: 12/19/2022] Open
Abstract
Clinical outcome in antibody-mediated rejection (AMR) shows high inter-individual heterogeneity. Sialylation status of the Fc fragment of IgGs is variable, which could modulate their ability to bind to C1q and/or Fc receptors. In this translational study, we evaluated whether DSA sialylation influence AMR outcomes. Among 938 kidney transplant recipients for whom a graft biopsy was performed between 2004 and 2012 at Lyon University Hospitals, 69 fulfilled the diagnosis criteria for AMR and were enrolled. Sera banked at the time of the biopsy were screened for the presence of DSA by Luminex. The sialylation status of total IgG and DSA was quantified using Sambucus nigra agglutinin-based chromatography. All patients had similar levels of sialylation of serum IgGs (~2%). In contrast, the proportion of sialylated DSA were highly variable (median = 9%; range = 0–100%), allowing to distribute the patients in two groups: high DSA sialylation (n = 44; 64%) and low DSA sialylation (n = 25; 36%). The two groups differed neither on the intensity of rejection lesions (C4d, ptc, and g; p > 0.05) nor on graft survival rates (Log rank test, p = 0.99). in vitro models confirmed the lack of impact of Fc sialylation on the ability of a monoclonal antibody to trigger classical complement cascade and activate NK cells. We conclude that DSA sialylation status is highly variable but has not impact on DSA pathogenicity and AMR outcome.
Collapse
Affiliation(s)
- Thomas Barba
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Jean Harb
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France.,Laboratory of Biochemistry, Nantes University Hospital, Nantes, France
| | | | - Alice Koenig
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Virginie Mathias
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,French National Blood Service (EFS), HLA Laboratory, Lyon, France
| | - Maud Rabeyrin
- Department of Pathology, Hospices Civils de Lyon, Bron, France
| | - Eric Pouliquen
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Antoine Sicard
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Dimitri Chartoire
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Emilie Dugast
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France
| | - Thierry Defrance
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Emmanuel Morelon
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Sophie Brouard
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France
| | - Valérie Dubois
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,French National Blood Service (EFS), HLA Laboratory, Lyon, France
| | - Olivier Thaunat
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| |
Collapse
|
5
|
Chen CC, Koenig A, Saison C, Dahdal S, Rigault G, Barba T, Taillardet M, Chartoire D, Ovize M, Morelon E, Defrance T, Thaunat O. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. Front Immunol 2018. [PMID: 29515582 PMCID: PMC5825980 DOI: 10.3389/fimmu.2018.00275] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Antibody-mediated rejection is currently the leading cause of transplant failure. Prevailing dogma predicts that B cells differentiate into anti-donor-specific antibody (DSA)-producing plasma cells only with the help of CD4+ T cells. Yet, previous studies have shown that dependence on helper T cells decreases when high amounts of protein antigen are recruited to the spleen, two conditions potentially met by organ transplantation. This could explain why a significant proportion of transplant recipients develop DSA despite therapeutic immunosuppression. Using murine models, we confirmed that heart transplantation, but not skin grafting, is associated with accumulation of a high quantity of alloantigens in recipients’ spleen. Nevertheless, neither naive nor memory DSA responses could be observed after transplantation of an allogeneic heart into recipients genetically deficient for CD4+ T cells. These findings suggest that DSA generation rather result from insufficient blockade of the helper function of CD4+ T cells by therapeutic immunosuppression. To test this second theory, different subsets of circulating T cells: CD8+, CD4+, and T follicular helper [CD4+CXCDR5+, T follicular helper cells (Tfh)], were analyzed in 9 healthy controls and 22 renal recipients. In line with our hypothesis, we observed that triple maintenance immunosuppression (CNI + MMF + steroids) efficiently blocked activation-induced upregulation of CD25 on CD8+, but not on CD4+ T cells. Although the level of expression of CD40L and ICOS was lower on activated Tfh of immunosuppressed patients, the percentage of CD40L-expressing Tfh was the same than control patients, as was Tfh production of IL21. Induction therapy with antithymocyte globulin (ATG) resulted in prolonged depletion of Tfh and reduction of CD4+ T cells number with depleting monoclonal antibody in murine model resulted in exponential decrease in DSA titers. Furthermore, induction with ATG also had long-term beneficial influence on Tfh function after immune reconstitution. We conclude that CD4+ T cell help is mandatory for naive and memory DSA responses, making Tfh cells attractive targets for improving the prevention of DSA generation and to prolong allograft survival. Waiting for innovative treatments to be translated into the clinical field ATG induction seems to currently offer the best clinical prospect to achieve this goal.
Collapse
Affiliation(s)
- Chien-Chia Chen
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,IHU OPERA, Cardioprotection Laboratory, Hospices Civils de Lyon, CIC, Bron, France
| | - Alice Koenig
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Carole Saison
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Edouard Herriot University Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France
| | - Suzan Dahdal
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Edouard Herriot University Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France
| | - Guillaume Rigault
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Thomas Barba
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Morgan Taillardet
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Dimitri Chartoire
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Michel Ovize
- IHU OPERA, Cardioprotection Laboratory, Hospices Civils de Lyon, CIC, Bron, France.,Lyon-Est Medical Faculty, Claude Bernard University Lyon 1, Lyon, France
| | - Emmanuel Morelon
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,IHU OPERA, Cardioprotection Laboratory, Hospices Civils de Lyon, CIC, Bron, France.,Edouard Herriot University Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University Lyon 1, Lyon, France
| | - Thierry Defrance
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Olivier Thaunat
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,IHU OPERA, Cardioprotection Laboratory, Hospices Civils de Lyon, CIC, Bron, France.,Edouard Herriot University Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University Lyon 1, Lyon, France
| |
Collapse
|
6
|
Sicard A, Koenig A, Graff-Dubois S, Dussurgey S, Rouers A, Dubois V, Blanc P, Chartoire D, Errazuriz-Cerda E, Paidassi H, Taillardet M, Morelon E, Moris A, Defrance T, Thaunat O. B Cells Loaded with Synthetic Particulate Antigens: A Versatile Platform To Generate Antigen-Specific Helper T Cells for Cell Therapy. Nano Lett 2016; 16:297-308. [PMID: 26650819 DOI: 10.1021/acs.nanolett.5b03801] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Adoptive cell therapy represents a promising approach for several chronic diseases. This study describes an innovative strategy for biofunctionalization of nanoparticles, allowing the generation of synthetic particulate antigens (SPAg). SPAg activate polyclonal B cells and vectorize noncognate proteins into their endosomes, generating highly efficient stimulators for ex vivo expansion of antigen-specific CD4+ T cells. This method also allows harnessing the ability of B cells to polarize CD4+ T cells into effectors or regulators.
Collapse
Affiliation(s)
- Antoine Sicard
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
- Edouard Herriot Hospital , Transplantation, Nephrology and Clinical Immunology Department, 69003 Lyon, France
| | - Alice Koenig
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
- Edouard Herriot Hospital , Transplantation, Nephrology and Clinical Immunology Department, 69003 Lyon, France
| | - Stéphanie Graff-Dubois
- Sorbonne University , UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center for Immunology and Microbial Infections - CIMI-Paris, F-75013, Paris, France
| | - Sébastien Dussurgey
- SFR Biosciences, UMS344/US8, Inserm, CNRS, Claude Bernard Lyon-1 University, Ecole Normale Supérieure , 69007 Lyon, France
| | - Angéline Rouers
- Sorbonne University , UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center for Immunology and Microbial Infections - CIMI-Paris, F-75013, Paris, France
| | - Valérie Dubois
- French National Blood Service (EFS) , 69007 Lyon, France
| | - Pascal Blanc
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
| | - Dimitri Chartoire
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
| | | | - Helena Paidassi
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
| | - Morgan Taillardet
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
| | - Emmanuel Morelon
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
- Edouard Herriot Hospital , Transplantation, Nephrology and Clinical Immunology Department, 69003 Lyon, France
| | - Arnaud Moris
- Sorbonne University , UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center for Immunology and Microbial Infections - CIMI-Paris, F-75013, Paris, France
| | - Thierry Defrance
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
| | - Olivier Thaunat
- International Center for Infectiology Research (CIRI); French National Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard Lyon 1 University; Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , 69007 Lyon, France
- Edouard Herriot Hospital , Transplantation, Nephrology and Clinical Immunology Department, 69003 Lyon, France
| |
Collapse
|